회원가입 | 연락처 | 사이트맵 | English       회사소개 | 리포트 | 커스텀 리서치 | 고객지원 리포트검색 정보제휴업체

로그인 카테고리 유/무선통신 전기/전자 디지털기기/미디어/방송 Information Technology 에너지 생명공학 화학/신소재 자동차 환경 일반소비재 마케팅/광고 금융 건설 교통/운송 소비자조사 방위/항공/우주 식음료 중공업 교육 기계 무역 스포츠/레저 해운/조선 패션 정부/정책 공예/귀금속 컴퍼니 프로파일 기타산업 무선통신 유선통신 차세대통신 홈네트워크 휴대폰/단말기 RFID IPTV/VoIP 통신융합 통신장비/네트워크 광통신/위성통신 국가별통신시장 기타 전자부품 디스플레이 반도체 조명/LED 로봇 센서 레이저 MEMS Embedded Software SoC 기타 디지털기기/가전 차세대정보기기 휴대용미디어기기 디지털컨텐츠 게임 방송/미디어/엔터테인먼트 STB 기타 e-Commerce e-Learning 보안 소프트웨어/서비스 인터넷 시스템장비 IT기술 기타 태양광발전 신/재생에너지 연료전지 배터리 전기/발전 석유/가스 에너지일반 기타 Digital Health/e-Health 바이오테크놀로지 생체인식 의료장비 제약 진단 헬스케어 기타 나노 신소재/신기술 플라스틱 섬유 폴리머 세라믹 금속/광물 화학 기타 전장 전자부품 텔레메틱스 전기자동차 자동차용품/산업 기타 리사이클 수처리 공기 오염 기타

현재위치 : HOME > 리포트 > 생명공학 > 제약 Biosimilars: Market Entry Strategies 발행사 Datamonitor 발행일 2011-12 분량 서비스형태 Report 판매가격 PDF Single User : $5,700 인쇄하기 Table of Contents EXECUTIVE SUMMARY Introduction Strategic scoping and focus Key findings Related reports BIOSIMILARS OFFER A RELATIVELY LOW RISK GROWTH STRATEGY FOR PHARMA Advantages for entering the biosimilar arena Capture a share of the fast growing biosimilars market Lower development costs and reduced risk of pipeline failures Leverages the branded sales model Biosimilars provide a more stable revenue stream Biosimilars have the potential to increase profit margins for generics producers External drivers of the biosimilars market Growing use of biologic products A number of blockbuster branded biologics will have expired by the end of 2016 The high cost of biologics will drive payers to look to biosimilars for cost-savings Biosimilars have seen growing payer and patient acceptance There are a growing number of navigable biosimilar approval pathways BIOSIMILAR DEAL TRENDS Interest in biosimilars varies among the top 50 pharma companies Actively interested in biosimilars Plan to enter the biosimilars arena Will avoid biosimilars Strategies used by the top 50 pharma companies to enter the biosimilars arena In-house development, partnership and acquisition deals Partnership and acquisition deals Development and commercialization deals Commercialization deals LEADING PHARMA COMPANIES ACTIVE IN BIOSIMILARS Merck & Co. (Merck BioVentures): four key deals have shaped its biosimilars capabilities Biosimilar portfolio Biosimilar deals and partnerships Pfizer: deal with Biocon provides access to biosimilar insulins Biosimilar portfolio Biosimilar deals and partnerships GlaxoSmithKline: opting for a cautious entry in biosimilars Biosimilar portfolio Biosimilar deals and partnerships Biogen Idec: perceives the biosimilars market to be a low risk strategy to generate additional revenue Biosimilar deals and partnerships Amgen: deal with Watson marks Amgen’s entrance into the biosimilars arena Biosimilar deals and partnerships Daiichi Sankyo (Ranbaxy): gains access to biosimilars via Ranbaxy Biosimilar portfolio Biosimilar deals and partnerships Sandoz: biosimilar success shaped largely through its acquisition of Hexal Biosimilar portfolio Biosimilar deals and partnerships Teva: acquisition of ratiopharm significantly bolstered biosimilar portfolio and capabilities Biosimilar portfolio Biosimilar deals and partnerships Hospira: partnerships have enabled the company to build a considerable biosimilars portfolio Biosimilar portfolio Biosimilar deals and partnerships Stada: turns to collaborations to share the costs and risks of developing biosimilars Biosimilar portfolio Biosimilar deals and partnerships Apotex: collaboration with Intas provides access to biosimilar filgrastim candidates Biosimilar portfolio Biosimilar deals and partnerships Watson: building upon its expertise in women’s health by licensing in biosimilar infertility candidate Biosimilar portfolio Biosimilar deals and partnerships Actavis: joint venture with Bioton provides access to biosimilar insulins Biosimilar portfolio Biosimilar deals and partnerships Mylan: joins forces with Biocon to develop biosimilars Biosimilar deals and partnerships LEADING PHARMA COMPANIES LOOKING TO ENTER THE BIOSIMILARS MARKET Boehringer Ingelheim: plans to capitalize on biopharmaceuticals contract manufacturing LEADING PHARMA COMPANIES THAT DO NOT PLAN TO ENTER BIOSIMILARS AstraZeneca: opts for biosuperiors rather than biosimilars Bayer: sees no attraction in entering the biosimilars sector Roche: determined to protect its leading biologics offering from biosimilar competition BIBLIOGRAPHY Publications and online articles Datamonitor reports and products APPENDIX Exchange rates used in this report TABLES Table: Comparison of operating margins for branded biologics, branded prescription pharma, and generics companies, 2010 Table: Estimated savings anticipated to be gained through the use of biosimilar drugs Table: Biosimilar and copy-biologic approval pathways Table: Interest in biosimilars among branded companies ranked among the to 50 pharma companies Table: Merck & Co. biosimilars portfolio, 2011 Table: Merck & Co. – deals targeting biosimilars Table: Pfizer biosimilar/copy-biologic portfolio, 2011 Table: Pfizer deals targeting biosimilars Table: GlaxoSmithKline biosimilars/copy-biologic portfolio, 2011 Table: GlaxoSmithKline deals targeting biosimilars Table: Biogen Idec deals targeting biosimilars Table: Amgen – deals targeting biosimilars Table: Ranbaxy biosimilars/copy-biologic portfolio, 2011 Table: Ranbaxy deals targeting biosimilars Table: Sandoz biosimilars portfolio, 2011 Table: Sandoz deals targeting biosimilars Table: Teva biosimilars portfolio, 2011 Table: Teva deals targeting biosimilars Table: Hospira biosimilars portfolio, 2011 Table: Hospira deals targeting biosimilars Table: Stada biosimilars portfolio, 2011 Table: Stada deals targeting biosimilars Table: Apotex biosimilars portfolio, 2011 Table: Apotex deals targeting biosimilars Table: Watson biosimilars portfolio, 2011 Table: Watson deals targeting biosimilars Table: Actavis biosimilars/copy-biologic portfolio, 2011 Table: Actavis – deals targeting biosimilars Table: Mylan deals targeting biosimilars Table: Currency exchange rates, 2011 FIGURES Figure: Advantages for entering the biosimilars market and external factors driving biosimilar growth Figure: Global biosimilar sales ($m), 2007–10 Figure: 2016 sales of biologics due to face patent expiry to 2016 for the top 50 pharma companies Figure: Deals made by the top 50 pharma companies to access biosimilars as well as enhance their biologic capabilities , 1999–2011 Figure: Competencies and challenges in biosimilars development Figure: Strategies used by leading pharma companies to directly access biosimilars Figure: Types of deals made by the top 50 pharma companies to access biosimilars as well as enhance their biologic capabilities, 1999–2011 Figure: Merck & Co. forecast global sales according to molecule type, 2010–16 Figure: Pfizer forecast global sales according to molecule type, 2010–16 Figure: GlaxoSmithKline forecast global sales according to molecule type, 2010–16 Figure: Biogen Idec forecast global sales according to molecule type, 2010–16 Figure: Amgen forecast global sales according to molecule type, 2010–16 Figure: Daiichi Sankyo forecast global sales according to molecule type, 2010–16 Figure: Boehringer Ingelheim forecast global sales according to molecule type, 2010–16 Figure: AstraZeneca forecast global sales according to molecule type, 2010–16 Figure: Bayer forecast global sales according to molecule type, 2010–16 Figure: Roche forecast global sales according to molecule type, 2010–16

회사소개 | 개인정보보호정책 | 이용약관 | 배송/결제안내 | 이용안내
		서울시 강남구 논현동 210-1 삼원빌딩 | 회사명 : (주)엘앤에치 대표전화 : 02-554-0001 / 팩스 : 02-3444-5501 / 이메일 : sales@landh.co.kr Copyright ⓒ 2008 LNH, Inc. All rights reserved.